{"id":749392,"date":"2025-06-26T17:38:01","date_gmt":"2025-06-26T17:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=749392"},"modified":"2025-06-26T17:38:01","modified_gmt":"2025-06-26T17:38:01","slug":"amyotrophic-lateral-sclerosis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-ionis-pharmaceuticals-1st-biotherapeutics-scholar-rock","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/amyotrophic-lateral-sclerosis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-ionis-pharmaceuticals-1st-biotherapeutics-scholar-rock_749392.html","title":{"rendered":"Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock"},"content":{"rendered":"
\n
\"Amyotrophic<\/a><\/div>\n
\n
Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight 2025<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cAmyotrophic Lateral Sclerosis (ALS) \u2013 Pipeline Insight, 2025,\u201d report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

Amyotrophic Lateral Sclerosis Pipeline constitutes 75+ key companies continuously working towards developing 80+ Amyotrophic Lateral Sclerosis treatment therapies, analyzes DelveInsight.<\/p>\n

Amyotrophic Lateral Sclerosis Overview:<\/strong><\/p>\n

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative condition that primarily targets motor neurons. The disease can arise from both genetic (familial) and non-genetic (sporadic) factors, though a single definitive cause has not been identified. ALS typically impacts both upper and lower motor neurons, beginning with limb weakness and gradually progressing to paralysis and, ultimately, death.<\/p>\n

The underlying cause of sporadic ALS remains largely unknown, though several mechanisms have been proposed, including disrupted RNA processing, oxidative stress from SOD1 mutations, inflammation, and glutamate toxicity. Familial ALS, which is less common, is linked to inherited genetic mutations such as expansions in the C9ORF72 gene and SOD1 gene mutations, typically passed down in an autosomal dominant manner.<\/p>\n

Breathing difficulties are a major concern in ALS due to respiratory muscle weakening. Noninvasive ventilation is commonly used to manage symptoms like shortness of breath or reduced forced vital capacity (FVC), while invasive ventilation may be required in more severe cases. Difficulty swallowing (dysphagia) is also frequent and may be managed through dietary modifications or, if necessary, feeding via a gastrostomy (G-tube) to prevent weight loss.<\/p>\n

ALS can lead to various complications, including respiratory failure, speech and mobility issues, malnutrition, fatigue, muscle spasms, and problems with saliva and mucus control. Additionally, medications used to manage ALS symptoms may cause side effects such as gastrointestinal discomfort, liver complications, or headaches.<\/p>\n

Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights @ https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr<\/a><\/strong><\/p>\n

“Amyotrophic Lateral Sclerosis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.<\/p>\n

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report<\/strong><\/p>\n